– USA, AZ – HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments and reagents for molecular profiling applications, today announced that Donnie (Don) M. Hardison has been appointed to its Board of Directors.
Don Hardison is an executive leader with extensive experience in diagnostic laboratory management, sales, marketing, strategy and operations. Mr. Hardison has experience as a public and private company CEO, led a successful initial public offering, and has held senior executive roles in emerging‑growth to large, well‑established companies in the clinical diagnostic and other relevant markets.
“We are incredibly honored to have Don join our Board,” said TJ Johnson, President and CEO of HTG Molecular Diagnostics. “Don’s career experience, industry knowledge and leadership capabilities will be tremendous assets for our Board and management team.”
Mr. Hardison was most recently the President and CEO, and served on the board of directors, of Good Start Genetics from April 2010 to March this year. For more than 20 years prior to that, Mr. Hardison held a number of executive and senior management positions at companies including Laboratory Corporation of America, or LabCorp, a clinical laboratory company, Exact Sciences Corporation, a molecular diagnostic company, OnTarget, Inc., a sales and marketing consulting company, Quest Diagnostics Inc., a clinical laboratory company, SmithKline Beecham Corporation, or SmithKline, a pharmaceutical company and others. Early in his career, Mr. Hardison spent 17 years in various roles of increasing responsibility with SmithKline. He also has served on the boards of directors of several private and public companies throughout his distinguished career.
“I am very excited to have the opportunity to work with TJ, his team and the Board as they continue their important work in democratizing NGS-based molecular profiling. I believe the company’s technology has the potential to enable more precise diagnosis and delivery of individually tailored treatment at the local level.” stated Mr. Hardison.
About HTG:
Headquartered in Tucson, Arizona, HTG’s mission is to empower precision medicine at the local level. In 2013 the company commercialized its HTG Edge instrument platform and a portfolio of RNA assays that leverage HTG’s proprietary nuclease protection chemistry. HTG’s product offerings have since expanded to include its HTG EdgeSeq product line, which automates sample and targeted library preparation for next-generation sequencing.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
